Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil.

Journal

Clinical pharmacokinetics

ISSN: 1179-1926

Titre abrégé: Clin Pharmacokinet

Pays: Switzerland

ID NLM: 7606849

Informations de publication

Date de publication:
03 Nov 2023

Historique:

accepted: 11 10 2023

medline: 3 11 2023

pubmed: 3 11 2023

entrez: 3 11 2023

Statut: aheadofprint

Résumé

Early investigations into drug-drug interactions (DDIs) involving cytochrome P450 2C8 (CYP2C8) have highlighted the complexity of interactions between CYP2C8 substrate drugs, including montelukast, desloratadine, pioglitazone, repaglinide, and cerivastatin (the latter two being OATP1B1 substrates), and standardized CYP2C8 inhibitors such as clopidogrel (Clop) and gemfibrozil (Gem). These interactions have proven challenging to predict based solely on simple CYP inhibition. A hypothesis has emerged suggesting that these substrate drugs first distribute to UDP-glucuronosyltransferase (UGT) before undergoing oxidation by CYP2C8, resulting in bidirectional elimination. The process of drug distribution to UGT is believed to significantly impact these DDIs. This study aims to explore the intricate interplay between UGT and CYP2C8 in the context of DDIs involving CYP2C8 substrates affected by Clop and Gem. Plasma-level data for the unchanged drug and its metabolite, drawn from the respective literature, formed the basis of our analysis. We evaluated the enzymatic inhibitory activities of DDIs and utilized simulations to estimate plasma levels of the unchanged victim drug and its metabolite in each DDI. This was accomplished by employing a functional relationship that considered the fractional contributions of CYP2C8 and UGT to clearance, perpetrator-specific inhibitory activities against CYP2C8, and drug distribution to UGT. Our findings emphasize the pivotal role of UGT-mediated distribution in the context of CYP2C8 substrate metabolism, particularly in the complex DDIs induced by Clop and Gem. In these DDIs, Gem exerts inhibitory effects on both UGT and CYP2C8, whereas Clop (specifically its metabolite, Clop-COOH) solely targets CYP2C8. Importantly, the inhibition of CYP2C8 by both Clop and Gem is achieved through a non-competitive mechanism, driven by the actions of their acyl-glucuronides. Clop and Gem exhibit inhibition activities accounting for 85% (pA These findings substantially enhance our comprehension of CYP2C8-mediated oxidation and DDIs, holding crucial implications for drug development and the planning of clinical trials involving these inhibitors.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE

METHODS METHODS

Plasma-level data for the unchanged drug and its metabolite, drawn from the respective literature, formed the basis of our analysis. We evaluated the enzymatic inhibitory activities of DDIs and utilized simulations to estimate plasma levels of the unchanged victim drug and its metabolite in each DDI. This was accomplished by employing a functional relationship that considered the fractional contributions of CYP2C8 and UGT to clearance, perpetrator-specific inhibitory activities against CYP2C8, and drug distribution to UGT.

RESULTS RESULTS

Our findings emphasize the pivotal role of UGT-mediated distribution in the context of CYP2C8 substrate metabolism, particularly in the complex DDIs induced by Clop and Gem. In these DDIs, Gem exerts inhibitory effects on both UGT and CYP2C8, whereas Clop (specifically its metabolite, Clop-COOH) solely targets CYP2C8. Importantly, the inhibition of CYP2C8 by both Clop and Gem is achieved through a non-competitive mechanism, driven by the actions of their acyl-glucuronides. Clop and Gem exhibit inhibition activities accounting for 85% (pA

CONCLUSION CONCLUSIONS

These findings substantially enhance our comprehension of CYP2C8-mediated oxidation and DDIs, holding crucial implications for drug development and the planning of clinical trials involving these inhibitors.

Identifiants

DOI: 10.1007/s40262-023-01322-7 PMID: 37921907

pubmed: 37921907

doi: 10.1007/s40262-023-01322-7

pii: 10.1007/s40262-023-01322-7

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi Y, Watabe T. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos. 1997;25(5):270–3.

pubmed: 9152608

Iga K. Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. J Pharm Sci. 2015;104(4):1478–91.

pubmed: 25558834 doi: 10.1002/jps.24320

Iga K. Simulation of metabolic drug-drug interactions perpetrated by fluvoxamine using hybridized two-compartment hepatic drug-pool-based tube modeling and estimation of in vivo inhibition constants. J Pharm Sci. 2015;104(10):3565–77.

pubmed: 26099559 doi: 10.1002/jps.24549

Iga K. Dynamic and static simulations of fluvoxamine-perpetrated drug-drug interactions using multiple cytochrome P450 inhibition modeling, and determination of perpetrator-specific CYP isoform inhibition constants and fractional CYP isoform contributions to victim clearance. J Pharm Sci. 2016;105(3):1307–17.

pubmed: 26886336 doi: 10.1016/j.xphs.2015.11.044

Iga K, Kiriyama A. Simulations of cytochrome P450 3A4-mediated drug-drug interactions by simple two-compartment model-assisted static method. J Pharm Sci. 2017;106(5):1426–38.

pubmed: 28089686 doi: 10.1016/j.xphs.2017.01.008

Iga K, Kiriyama A. Usefulness of two-compartment model-assisted and static overall inhibitory-activity method for prediction of drug-drug interaction. Biol Pharm Bull. 2017;40(12):2024–37.

pubmed: 28993551 doi: 10.1248/bpb.b17-00512

Backman JT, Filppula AM, Niemi M, Neuvonen PJ. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016;68(1):168–241.

pubmed: 26721703 doi: 10.1124/pr.115.011411

Karonen T, Neuvonen PJ, Backman JT. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br J Clin Pharmacol. 2012;73(2):257–67.

pubmed: 21838784 pmcid: 3269585 doi: 10.1111/j.1365-2125.2011.04086.x

Itkonen MK, Tornio A, Filppula AM, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel but not prasugrel significantly inhibits the CYP2C8-mediated metabolism of montelukast in humans. Clin Pharmacol Ther. 2018;104(3):495–504.

pubmed: 29171020 doi: 10.1002/cpt.947

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel and gemfibrozil strongly inhibit the CYP2C8-dependent formation of 3-hydroxydesloratadine and increase desloratadine exposure in humans. Drug Metab Dispos. 2019;47(4):377–85.

pubmed: 30630815 doi: 10.1124/dmd.118.084665

Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. 2003;46(3):347–51.

pubmed: 12687332 doi: 10.1007/s00125-003-1034-7

Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos. 2006;34(1):191–7.

pubmed: 16299161 doi: 10.1124/dmd.105.007633

Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos. 2009;37(12):2359–66.

pubmed: 19773535 doi: 10.1124/dmd.109.029728

Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyrönen TH, Tapaninen T, Neuvonen PJ, Niemi M, Backman JT. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther. 2014;96(4):498–507.

pubmed: 24971633 doi: 10.1038/clpt.2014.141

Kahma H, Filppula AM, Neuvonen M, Tarkiainen EK, Tornio A, Holmberg MT, Itkonen MK, Finel M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel carboxylic acid glucuronidation is mediated mainly by UGT2B7, UGT2B4, and UGT2B17: implications for pharmacogenetics and drug-drug interactions. Drug Metab Dispos. 2018;46(2):141–50.

pubmed: 29138287 doi: 10.1124/dmd.117.078162

Takagi M, Sakamoto M, Itoh T, Fujiwara R. Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. Drug Metab Pharmacokinet. 2015;30(4):288–94.

pubmed: 26195223 doi: 10.1016/j.dmpk.2015.05.001

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther. 2011;89(4):579–86.

pubmed: 21368757 doi: 10.1038/clpt.2010.358

Shah MB. Inhibition of CYP2C8 by acyl glucuronides of gemfibrozil and clopidogrel: pharmacological significance, progress and challenges. Biomolecules. 2022;12(9):1218.

pubmed: 36139056 pmcid: 9496539 doi: 10.3390/biom12091218

Tornio A, Neuvonen PJ, Niemi M, Backman JT. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opin Drug Metab Toxicol. 2017;13(1):83–95.

pubmed: 27548563 doi: 10.1080/17425255.2016.1227791

Nishihara M, Sudo M, Kamiguchi H, Kawaguchi N, Maeshiba Y, Kiyota Y, Takahashi J, Tagawa Y, Kondo T, Asahi S. Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro. Drug Metab Pharmacokinet. 2012;27(2):223–31.

pubmed: 22123126 doi: 10.2133/dmpk.DMPK-11-RG-061

Nishihara M, Sudo M, Kawaguchi N, Takahashi J, Kiyota Y, Kondo T, Asahi S. An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide. Drug Metab Dispos. 2012;40(2):249–58.

pubmed: 22028317 doi: 10.1124/dmd.111.040105

Stringer F, Scott G, Valbuena M, Kinley J, Nishihara M, Urquhart R. The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent. Eur J Clin Pharmacol. 2013;69(3):423–30.

pubmed: 22960998 doi: 10.1007/s00228-012-1382-7

Kazmi F, Barbara JE, Yerino P, Parkinson A. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab Dispos. 2015;43(4):523–33.

pubmed: 25595597 doi: 10.1124/dmd.114.062620

Kazmi F, Yerino P, Barbara JE, Parkinson A. Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab Dispos. 2015;43:1294–302.

pubmed: 26135009 doi: 10.1124/dmd.115.065011

Gan J, Chen W, Shen H, Gao L, Hong Y, Tian Y, Li W, Zhang Y, Tang Y, Zhang H, Humphreys WG, Rodrigues AD. Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol. 2010;70(6):870–80.

pubmed: 21175442 pmcid: 3014070 doi: 10.1111/j.1365-2125.2010.03772.x

VandenbBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos. 2011;39(9):1546–54.

doi: 10.1124/dmd.111.039065

Cardoso JO, Oliveira RV, Lu JBL, Desta Z. In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015;43(12):1905–16.

pubmed: 26374173 pmcid: 4658491 doi: 10.1124/dmd.115.065763

Ma Y, Fu Y, Khojasteh SC, Dalvie D, Zhang D. Glucuronides as potential anionic substrates of human cytochrome P450 2C8 (CYP2C8). J Med Chem. 2017;60(21):8691–705.

pubmed: 28653847 doi: 10.1021/acs.jmedchem.7b00510

Parkinson A, Kazmi F, Buckley DB, Yerino P, Ogilvie BW, Paris BL. System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metab Pharmacokinet. 2010;25(1):16–27.

pubmed: 20208386 doi: 10.2133/dmpk.25.16

Liu Y, Coughtrie MWH. Revisiting the latency of uridine diphosphate-glucuronosyltransferases (UGTs)-how does the endoplasmic reticulum membrane influence their function? Pharmaceutics. 2017;9(3):32.

pubmed: 28867809 pmcid: 5620573 doi: 10.3390/pharmaceutics9030032

Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005;77(5):404–14.

pubmed: 15900286 doi: 10.1016/j.clpt.2004.12.266

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel markedly increases plasma concentrations of CYP2C8 substrate pioglitazone. Drug Metab Dispos. 2016;44(8):1364–71.

pubmed: 27260150 doi: 10.1124/dmd.116.070375

Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. 2002;72(6):685–91.

pubmed: 12496749 doi: 10.1067/mcp.2002.128469

Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Affrime M. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet. 2002;41Suppl 1:29–35.

doi: 10.2165/00003088-200241001-00005

Banfield C, Herron J, Keung A, Padhi D, Affrime M. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet. 2002;41Suppl 1:37–44.

doi: 10.2165/00003088-200241001-00006

Cheng H, Leff JA, Amin R, Gertz BJ, Smet MD, Noonan N, Rogers JD, Malbecq W, Meisner D, Somers G. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res. 1996;13(3):445–8.

pubmed: 8692739 doi: 10.1023/A:1016056912698

Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004;18(4):399–411.

pubmed: 15312146 doi: 10.1111/j.1472-8206.2004.00254.x

Hu G, Johnson EF, Kemper B. CYP2C8 exists as a dimer in natural membranes. Drug Metab Dispos. 2010;38(11):1976–83.

pubmed: 20699412 pmcid: 2967391 doi: 10.1124/dmd.110.034942

Fujiwara R, Yokoi T, Nakajima M. Structure and protein-protein interactions of human UDP-glucuronosyltransferases. Front Pharmacol. 2016;7:388.

pubmed: 27822186 pmcid: 5075577 doi: 10.3389/fphar.2016.00388

Uchiyama M, Fischer T, Mueller J, Oguchi M, Yamamura N, Koda H, Iwabuchi H, Izumi T. Identification of novel metabolic pathways of pioglitazone in hepatocytes: N-glucuronidation of thiazolidinedione ring and sequential ring-opening pathway. Drug Metab Dispos. 2010;38(6):946–56.

pubmed: 20185540 doi: 10.1124/dmd.109.031583

Säll C, Houston JB, Galetin A. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab Dispos. 2012;40(7):1279–89.

pubmed: 22451699 doi: 10.1124/dmd.112.045286

Schirris TJJ, Ritschel T, Bilos A, Smeitink JAM, Russel FGM. Statin lactonization by uridine 5’-diphospho-glucuronosyltransferases (UGTs). Mol Pharm. 2015;12(11):4048–55.

pubmed: 26412035 doi: 10.1021/acs.molpharmaceut.5b00474

Varma MVS, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res. 2013;30(4):1188–99.

pubmed: 23307347 doi: 10.1007/s11095-012-0956-5

Kudo T, Hisaka A, Sugiyama Y, Ito K. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. Drug Metab Dispos. 2013;41(2):362–71.

pubmed: 23139378 doi: 10.1124/dmd.112.049460

Kim SJ, Toshimoto K, Yao Y, Yoshikado T, Sugiyama Y. Quantitative analysis of complex drug-drug interactions between repaglinide and cyclosporin A/gemfibrozil using physiologically based pharmacokinetic models with in vitro transporter/enzyme inhibition data. J Pharm Sci. 2017;106(9):2715–26.

pubmed: 28479356 doi: 10.1016/j.xphs.2017.04.063

Yao Y, Toshimoto K, Kim SJ, Yoshikado T, Sugiyama Y. Quantitative analysis of complex drug-drug interactions between cerivastatin and metabolism/transport inhibitors using physiologically based pharmacokinetic modeling. Drug Metab Dispos. 2018;46(7):924–33.

pubmed: 29712725 doi: 10.1124/dmd.117.079210

Lee D, Doddapaneni S. Clinical pharmacology and biopharmaceutics reviews, FDA drug approval package of rozerem (ramelteon) tablets (application number 21-782). Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf . Accessed 27 Oct 2023.